Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 14
Phase 22

Trial Status

Completed2
Recruiting1
Terminated1

Role Distribution

Principal Investigator4
PI Rate100%

Activity Timeline

Clinical Trials (4)

NCT06431243Phase 1/2Recruiting
A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors
Advanced Solid Tumor
PrincipalinvestigatorStart date: 2024-05-08
NCT05621525Phase 1Terminated
Phase I Study of the BBP-398 in Patients With Advance Solid Tumors
Advanced or Metastatic Non-small Cell Lung CancerAdvanced Solid Tumor
PrincipalinvestigatorStart date: 2022-10-18
NCT05153343Phase 1/2Completed
Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative
Myelofibrosis,MFMyeloproliferative Neoplasm (MPN)
PrincipalinvestigatorStart date: 2021-12-27
NCT05526313Phase 1Completed
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant
Diffuse Large B Cell Lymphoma,DLBCL
PrincipalinvestigatorStart date: 2020-08-10

Research Network

Collaboration Network

21 collaborators·20 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

ting Niu, doctor

West China Hospital

Moderately Similar
7 trials

Shared therapeutic areas:

Diffuse Large B Cell Lymphoma,DLBCLMyelofibrosis,MFMyeloproliferative Neoplasm (MPN)

Worked with same sponsors:

Chengdu Zenitar Biomedical Technology Co., Ltd
Collaborated on 2 trials
Similarity Score38%

Li Zhang, Master

West China Hospital

Related
1 trials

Shared therapeutic areas:

Advanced or Metastatic Non-small Cell Lung CancerAdvanced Solid Tumor

Worked with same sponsors:

LianBio LLC
Collaborated on 1 trial
Similarity Score24%

Herui Yao, Doctor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Related
2 trials

Shared therapeutic areas:

Advanced Solid Tumor

Worked with same sponsors:

Chengdu Zenitar Biomedical Technology Co., Ltd
Collaborated on 1 trial
Similarity Score14%

Anish Thomas, M.D.

National Cancer Institute (NCI)

Related
9 trials

Shared therapeutic areas:

Advanced Solid Tumor
Similarity Score6%

Philippe Cassier, MD

Centre Leon Berard

Related
6 trials

Shared therapeutic areas:

Advanced Solid Tumor
Similarity Score6%

Jane Robertson

AstraZeneca

Related
10 trials

Shared therapeutic areas:

Advanced Solid Tumor
Similarity Score6%

Shun Lu

Shanghai Chest Hospital

Related
6 trials

Shared therapeutic areas:

Advanced Solid Tumor
Similarity Score6%

Javier Martín Broto

Hospital Universitario Fundación Jiménez Díaz

Related
5 trials

Shared therapeutic areas:

Advanced Solid Tumor
Similarity Score6%

Ezra Cohen, MD

University of Chicago

Related
6 trials

Shared therapeutic areas:

Advanced Solid Tumor
Similarity Score6%

Javier Martínez Trufero

Hospital Miguel Servet

Related
2 trials

Shared therapeutic areas:

Advanced Solid Tumor
Similarity Score6%

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT06431243Phase 1/2PrincipalInvestigator

A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumor
Recruiting
NCT05621525Phase 1PrincipalInvestigator

Phase I Study of the BBP-398 in Patients With Advance Solid Tumors

Advanced or Metastatic Non-small Cell Lung CancerAdvanced Solid Tumor
Terminated
NCT05153343Phase 1/2PrincipalInvestigator

Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative

Myelofibrosis,MFMyeloproliferative Neoplasm (MPN)
Completed
NCT05526313Phase 1PrincipalInvestigator

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

Diffuse Large B Cell Lymphoma,DLBCL
Completed

All 4 trials loaded